<i>MECOM</i> fusion partner and bone marrow blast percentage influence outcomes of patients with <i>MECOM</i> rearranged acute myeloid leukaemia
Wei‐Ying Jen(The University of Texas MD Anderson Cancer Center), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center), Guillermo Montalban‐Bravo(The University of Texas MD Anderson Cancer Center), Koji Sasaki(The University of Texas MD Anderson Cancer Center), Álex Bataller(The University of Texas MD Anderson Cancer Center), Jennifer Croden(University of Alberta), Naval Daver(The University of Texas MD Anderson Cancer Center), Ian Bouligny(The University of Texas MD Anderson Cancer Center), Gautam Borthakur, Sanam Loghavi(The University of Texas MD Anderson Cancer Center), Ghayas C. Issa(The University of Texas MD Anderson Cancer Center), Alexandre Bazinet(Jewish General Hospital), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Uday Popat(The University of Texas MD Anderson Cancer Center), Sherry Pierce(The University of Texas MD Anderson Cancer Center), Kapil N. Bhalla(University of South Florida), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Eitan Kugler(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Guilin Tang(The University of Texas MD Anderson Cancer Center), Gökçe Törüner(The University of Texas MD Anderson Cancer Center)
Cited by 3
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k